Filing Flows › Protalix BioTherapeutics (PLX) › Free cash flow
Protalix BioTherapeutics (PLX) free cash flow by quarter
Protalix BioTherapeutics' free cash flow was $21.3M in Q1 2026 (first quarter 2026), up 13-fold from Q4 2025. Over the last 3 quarters it ranged from $1.6M (Q4 2025) to $21.3M (Q1 2026).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q1 2026 | $21.3M | 13× | — |
| Q4 2025 | $1.6M | -54% | -54% |
| Q4 2024 | $3.6M | — | — |
Q1 2026 at a glance
Protalix BioTherapeutics, Q1 2026: revenue $33.8M (+234% year over year), operating margin 62.7%, net earnings $18.3M, operating cash flow $22.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Protalix BioTherapeutics' free cash flow?
Protalix BioTherapeutics' free cash flow was $21.3M in Q1 2026 (first quarter 2026), up 13-fold from Q4 2025.
How has Protalix BioTherapeutics' free cash flow changed?
Over the last 3 quarters it ranged from $1.6M (Q4 2025) to $21.3M (Q1 2026).
Q1 2026 results → · How Protalix BioTherapeutics makes money →